Tag Archives: Sandoz

Financial Daily Dose 3.3.2020 | Top Story: Promised Central Bank Action Halts Market Slide (for now)

BY: Michael D. Reif | March 3, 2020

Despite news of additional COVID-19-related deaths and infections in America, central bankers appear to have bought at least one day of peace for US markets, which posted strong gains on a late surge on Monday, breaking a week straight of losses – NYTimes and WSJ and Bloomberg and MarketWatch That said, all remains far from … Continue reading

When Time is Money

BY: Sharon Roberg-Perez | December 27, 2016

As the Biologics market is predicted to be a $250 billion market in the next few years, it is not surprising that parties embroiled in biosimilar litigation go to the mat. Both Apotex and Sandoz filed cert petitions this year in their cases against Amgen. The issue? A provision in 2010’s Biologics Price Competition and … Continue reading